<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01736475</url>
  </required_header>
  <id_info>
    <org_study_id>261201</org_study_id>
    <secondary_id>2012-003599-38</secondary_id>
    <nct_id>NCT01736475</nct_id>
  </id_info>
  <brief_title>Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)</brief_title>
  <official_title>A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients With Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess efficacy and safety, including immunogenicity of BAX 855 administered as
      prophylaxis and as on-demand therapy in adult and adolescent (12-65 years) previously treated
      patients (PTPs) with severe hemophilia A To determine the pharmacokinetic (PK) parameters of
      BAX 855.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Bleeding Rate (ABR)</measure>
    <time_frame>9 months</time_frame>
    <description>Comparisons between prophylactic and on-demand treatment were based on ABR estimates from a negative binomial regression model, taking into account the treatment regimen, target joints and age at screening, and duration of the observation period for efficacy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Success of BAX 855 for Treatment of Bleeding Episodes</measure>
    <time_frame>At least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm and 6 months (± 2 weeks) for the on-demand arm.</time_frame>
    <description>Success in the control of bleeding was defined as a rating of excellent or good using the Efficacy Rating Scale for Treatment of Bleeding Episodes measured 24 hours after initiation of treatment for the bleeding episode. EXCELLENT: Full relief of pain and cessation of objective signs of bleeding (eg, swelling, tenderness, and decreased range of motion in the case of musculoskeletal hemorrhage) after a single infusion. No additional infusion is required for the control of bleeding. Administration of further infusions to maintain hemostasis would not affect this scoring. GOOD: Definite pain relief and/or improvement in signs of bleeding after a single infusion. Possibly requires more than 1 infusion for complete resolution. FAIR: Probable and/or slight relief of pain and slight improvement in signs of bleeding after a single infusion. Required more than 1 infusion for complete resolution. NONE: No improvement or condition worsens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Number of BAX 855 Infusions Needed for the Treatment of Bleeding Episodes</measure>
    <time_frame>From first exposure to BAX 855 until the end of the study, [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm; and 6 months (± 2 weeks) for the on-demand arm].</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ≤1, 2, 3, 4, 5, 6, or &gt;6 Month Time Intervals Between Bleeding Episodes or no Bleeding Episodes</measure>
    <time_frame>From first exposure to BAX 855 until the end of the study, [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm; and 6 months (± 2 weeks) for the on-demand arm].</time_frame>
    <description>Interval between Bleeds in months was calculated as: Observation period for efficacy (in days)/(number of bleeds)*(12/365.2425)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-adjusted Consumption of BAX 855 - Per Prophylactic Infusion and Pharmacokinetic (PK) Infusion</measure>
    <time_frame>Prophylactic Infusion: ≥50 exposure days or 6 months (±2 weeks), whichever occurs last. PK Infusion: PK #1 Pre-infusion within 30 minutes; Post-infusion 10 min, and 0.5, 1, 3, 6, 24, 32, 48, 56 hours (h). PK #2 also at Post-infusion 96h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-adjusted Consumption of BAX 855 - Per Treatment of Bleeding Episode (BE) and Per BE for Maintenance of Hemostasis</measure>
    <time_frame>Treatment of Bleeding Episode (BE): Minor/Moderate BE every 12 to 24 hours until bleeding is resolved; Major BE every 8 to 12 hours until bleeding is resolved. Per BE for Maintenance of Hemostasis: within 48 hours after bleeding episode resolution.</time_frame>
    <description>Infusions per bleeding episode for maintenance of hemostasis only includes infusions following the resolution of a bleed to maintain hemostasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>From first exposure to BAX 855 until the end of the study, [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm; and 6 months (± 2 weeks) for the on-demand arm].</time_frame>
    <description>Adverse Events (AEs) and Serious Adverse Events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity - Number of Participants With Positive Inhibitory Antibodies to FVIII, Binding Antibodies to FVIII, PEG-VIII, PEG and Anti-CHO Antibodies at Study Completion/Termination</measure>
    <time_frame>From first exposure to BAX 855 until the end of the study, [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm; and 6 months (± 2 weeks) for the on-demand arm].</time_frame>
    <description>Number of participants who received BAX855, with immunogenicity data from study completion/termination visit.
FVIII = factor VIII; PEG-VIII = polyethylene glycol-factor VIII; Anti-CHO = Anti-Chinese hamster ovary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes: Haemo-SYM Questionnaire, Change in Score From Baseline to End of Study</measure>
    <time_frame>Baseline; and end of study visit [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm and 6 months (± 2 weeks) for the on-demand arm].</time_frame>
    <description>The HAEMO-SYM has two subscales: pain and bleeds. HAEMO-SYM subscale scores are calculated by taking the mean of the items in each subscale and transforming them to a 0 (none or absent) to 100 (very severe) scale.
Given that higher scores indicate more severe symptoms on the Haemo-SYM and that the change scores were calculated as the value at study completion minus the value at baseline, a negative change score indicates an improvement (reduction in symptoms). Conversely, a positive change score indicates worsening symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes - Short Form (SF)-36, Change From Baseline to End of Study</measure>
    <time_frame>Baseline; and end of study visit [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm and 6 months (± 2 weeks) for the on-demand arm]</time_frame>
    <description>Change from Baseline to End of Study for SF-36 Questionnaire is provided. Scores for individual SF-36 categories range from 0 to 100 with higher scores representing better health. Given that higher scores indicate better health-related quality of life (HRQoL) and that the change scores were calculated as the value at study completion minus the value at baseline, a negative change score indicates a worsening of HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Pk) - Plasma Half-life (One-stage Clotting Assay)</measure>
    <time_frame>Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only).</time_frame>
    <description>Terminal half-life calculated as log_e2/λz where λz is the terminal elimination rate constant.
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Pk) - Mean Residence Time (One-stage Clotting Assay)</measure>
    <time_frame>Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only).</time_frame>
    <description>The mean residence time (MRT) w as calculated as total area under the moment curve divided by the total area under the curve starting from the begin of infusion (or the end of infusion if start time is not available).
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Pk) - Total Body Clearance (One-stage Clotting Assay)</measure>
    <time_frame>Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only).</time_frame>
    <description>Clearance in dL/(kg.h) will be calculated as the dose in IU/kg divided by the total area under the curve starting from the begin of infusion (or the end of infusion if start time is not available).
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Pk) - Incremental Recovery Over Time (One-stage Clotting Assay)</measure>
    <time_frame>Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only).</time_frame>
    <description>Incremental recovery (IR) in (IU/dL)/ (IU/kg) calculated as: IR = (Cmax- (C pre-infusion)) / (Dose/kg), where C =concentration.
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Pk) - Area Under the Concentration Versus Time Curve From 0 to Infinity (AUC0-∞) (One-stage Clotting Assay)</measure>
    <time_frame>Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only).</time_frame>
    <description>Calculated by WinNonlin NCA (Model 201, calculation method: Linear Trapezoidal Linear/Log Interpolation).
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Pk) - Apparent Volume of Distribution at Steady State (Vss) (One-stage Clotting Assay)</measure>
    <time_frame>Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only).</time_frame>
    <description>The apparent volume of distribution at steady state (Vss) will be calculated as: Vss = Clearance * Mean Residence Time.
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Pk) - Maximum Plasma Concentration (Cmax) (One-stage Clotting Assay)</measure>
    <time_frame>Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only).</time_frame>
    <description>Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Pk) -Time to Maximum Concentration in Plasma (Tmax) (One-stage Clotting Assay)</measure>
    <time_frame>Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only).</time_frame>
    <description>Tmax in hours will be defined as the time to reach Cmax. Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vital Signs From Screening - Temperature</measure>
    <time_frame>Screening, week 2, week 4, exposure day 10-15, month 3, study completion/termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vital Signs From Screening - Pulse Rate</measure>
    <time_frame>Screening, week 2, week 4, exposure day 10-15, month 3, study completion/termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vital Signs From Screening - Respiratory Rate</measure>
    <time_frame>Screening, week 2, week 4, exposure day 10-15, month 3, study completion/termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Vital Signs From Screening - Blood Pressure</measure>
    <time_frame>Screening, week 2, week 4, exposure day 10-15, month 3, study completion/termination</time_frame>
    <description>Systolic Blood Pressure (SBP) Diastolic Blood Pressure (DBP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Clinical Chemistry Laboratory Assessments From Screening - Albumin and Protein</measure>
    <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Clinical Chemistry Laboratory Assessments From Screening - Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase</measure>
    <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
    <description>Alkaline Phosphatase (Alk Phos); Alanine Aminotransferase (Ala Amino); Aspartate Aminotransferase (Asp Amino)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Clinical Chemistry Laboratory Assessments From Screening - Bicarbonate, Chloride, Glucose, Potassium, Sodium, Blood Urea Nitrogen (BUN)</measure>
    <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Clinical Chemistry Laboratory Assessments From Screening - Creatinine, and Bilirubin</measure>
    <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hematology Laboratory Assessments From Screening - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes</measure>
    <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hematology Laboratory Assessments From Screening - Hematocrit</measure>
    <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hematology Laboratory Assessments From Screening - Hemoglobin</measure>
    <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hematology Laboratory Assessments From Screening - Erythrocytes</measure>
    <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Lipid Panel Assessments From Screening - Cholesterol; High Density Lipoprotein (HDL); Low Density Lipoprotein (LDL); Triglycerides; and Very Low Density Lipoprotein (VLDL)</measure>
    <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>On-demand</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method</intervention_name>
    <description>Pharmacokinetic (PK) evaluation of ADVATE</description>
    <arm_group_label>Prophylaxis</arm_group_label>
    <other_name>ADVATE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEGylated Recombinant Factor VIII</intervention_name>
    <description>Pharmacokinetic (PK) evaluation of BAX 855</description>
    <arm_group_label>Prophylaxis</arm_group_label>
    <other_name>BAX 855</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEGylated Recombinant Factor VIII</intervention_name>
    <description>Prophylaxis treatment</description>
    <arm_group_label>Prophylaxis</arm_group_label>
    <other_name>BAX 855</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEGylated Recombinant Factor VIII</intervention_name>
    <description>On-demand treatment</description>
    <arm_group_label>On-demand</arm_group_label>
    <other_name>BAX 855</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Participant and/or legal representative has/have voluntarily provided signed informed
             consent

          -  Participant is 12 to 65 years old at the time of screening

          -  Participant is male with severe hemophilia A (Factor VIII (FVIII) clotting activity &lt;
             1%) as confirmed by central laboratory at screening after the appropriate washout
             period or a documented FVIII clotting activity &lt;1%

          -  Participant has been previously treated with plasma-derived FVIII concentrates or
             recombinant FVIII for ≥150 documented exposure days (EDs)

          -  Participant is currently receiving prophylaxis or on-demand therapy with FVIII

          -  Participant is willing and able to comply with the requirements of the protocol

        Main Exclusion Criteria:

          -  Participant has detectable FVIII inhibitory antibodies (≥ 0.6 Bethesda Units (BU)
             using the Nijmegen modification of the Bethesda assay) as confirmed by central
             laboratory at screening

          -  Participant has history of FVIII inhibitory antibodies (≥ 0.4 BU using the Nijmegen
             modification of the Bethesda assay or ≥ 0.6 BU using the Bethesda assay) at any time
             prior to screening

          -  Participant has been diagnosed with an inherited or acquired hemostatic defect other
             than hemophilia A (eg, qualitative platelet defect or von Willebrand's disease).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitt Abbuehl, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Innovations GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida, College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bleeding and Clotting Disorders Institute</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Medical School</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals &amp; Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College-New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Health</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puget Sound Blood Group</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fremantle Hospital</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollywood Specialist Centre</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landes-Frauen-und Kinderklinik Linz</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH - Medizinische Universität Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHAT of Oncohaematology Diseases</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>61300</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gerinnungszentrum Rhein-Ruhr</name>
      <address>
        <city>Duisburg</city>
        <state>Nordrhein Westfalen</state>
        <zip>47051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum im Friedrichshain - Landsberger Allee</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Werlhof-Institut MVZ</name>
      <address>
        <city>Hannover</city>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi-Ken</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Occupational and Environmental Health Hospital</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka-Ken</state>
        <zip>807-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima-Ken</state>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine Hospital</name>
      <address>
        <city>Nishinomiya-shi</city>
        <state>Hyogo-Ken</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marianna University School of Medicine Hospital</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa-Ken</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital</name>
      <address>
        <city>Kashihara-shi</city>
        <state>Nara-Ken</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo-To</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ogikubo Hospital</name>
      <address>
        <city>Suginami-ku</city>
        <state>Tokyo-To</state>
        <zip>167-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun-gun</city>
        <state>Jeollanam-do</state>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>302-120</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung hee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <zip>134-727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <zip>682-714</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santariskiu Clinics, Public Institution</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penang General Hospital</name>
      <address>
        <city>Penang</city>
        <state>Pulau Pinang</state>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Tengku Ampuan Rahimah</name>
      <address>
        <city>Klang</city>
        <state>Selangor</state>
        <zip>41200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusat Darah Negara</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im.M.Kopernika w Lodzi</name>
      <address>
        <city>Lodz</city>
        <zip>93-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanador SRL</name>
      <address>
        <city>Bucuresti</city>
        <zip>011026</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <state>La Coruña</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Malaga</name>
      <address>
        <city>Malaga</city>
        <state>Málaga</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skånes Universitetssjukhus, Malmö</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset, Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsspital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI V.K.Gusak Emergency and Reconstructive Surgery Institute of NAMSU Center of IT</name>
      <address>
        <city>Donetsk</city>
        <zip>83045</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI Institute of Blood Pathology and Transfusion Medicine of NAMSU</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <state>Avon</state>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Thomas' Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2012</study_first_submitted>
  <study_first_submitted_qc>November 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <results_first_submitted>March 4, 2016</results_first_submitted>
  <results_first_submitted_qc>July 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 7, 2016</results_first_posted>
  <disposition_first_submitted>October 14, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>October 30, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 26, 2015</disposition_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled (signed informed consent) at 72 sites.</recruitment_details>
      <pre_assignment_details>A total of 159 participants provided informed consent and were screened for study participation, of which there were 21 screen failures. 138 participants were assigned to the prophylactic arm or the on-demand treatment regimen.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Prophylaxis</title>
          <description>Twice weekly at a dose of 45 ± 5 IU/kg</description>
        </group>
        <group group_id="P2">
          <title>On-demand</title>
          <description>10 to 60 ± 5 IU/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other - Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other - Surgical procedure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Study Participants</population>
      <group_list>
        <group group_id="B1">
          <title>Prophylaxis</title>
        </group>
        <group group_id="B2">
          <title>On-demand</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="138"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.8" spread="12.53"/>
                    <measurement group_id="B2" value="31.5" spread="11.05"/>
                    <measurement group_id="B3" value="30.0" spread="12.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annualized Bleeding Rate (ABR)</title>
        <description>Comparisons between prophylactic and on-demand treatment were based on ABR estimates from a negative binomial regression model, taking into account the treatment regimen, target joints and age at screening, and duration of the observation period for efficacy.</description>
        <time_frame>9 months</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
          </group>
        </group_list>
        <measure>
          <title>Annualized Bleeding Rate (ABR)</title>
          <description>Comparisons between prophylactic and on-demand treatment were based on ABR estimates from a negative binomial regression model, taking into account the treatment regimen, target joints and age at screening, and duration of the observation period for efficacy.</description>
          <population>Full Analysis Set</population>
          <units>Bleeds per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="3.4" upper_limit="5.5"/>
                    <measurement group_id="O2" value="43.4" lower_limit="25.2" upper_limit="74.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ratio Annualized Bleeding Rate (ABR) Prophylaxis/On-demand: Prophylaxis treatment w ill be considered to be successful if the upper limit of the 95% CI for the ratio between treatment regimen does not exceed 0.5 (corresponding to a 50% reduction of the mean ABR compared to the on-demand treatment). H01: μ1 ≥0.5*μ2 Ha1: μ1&lt;0.5*μ2 w here μ1 and μ2 are the mean ABRs in on prophylaxis and on-demand, respectively</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Negative binomial</method>
            <param_type>Ratio of means</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Success of BAX 855 for Treatment of Bleeding Episodes</title>
        <description>Success in the control of bleeding was defined as a rating of excellent or good using the Efficacy Rating Scale for Treatment of Bleeding Episodes measured 24 hours after initiation of treatment for the bleeding episode. EXCELLENT: Full relief of pain and cessation of objective signs of bleeding (eg, swelling, tenderness, and decreased range of motion in the case of musculoskeletal hemorrhage) after a single infusion. No additional infusion is required for the control of bleeding. Administration of further infusions to maintain hemostasis would not affect this scoring. GOOD: Definite pain relief and/or improvement in signs of bleeding after a single infusion. Possibly requires more than 1 infusion for complete resolution. FAIR: Probable and/or slight relief of pain and slight improvement in signs of bleeding after a single infusion. Required more than 1 infusion for complete resolution. NONE: No improvement or condition worsens.</description>
        <time_frame>At least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm and 6 months (± 2 weeks) for the on-demand arm.</time_frame>
        <population>Full Analysis Set - All bleeding episodes treated with BAX 855 in participants on on-demand and prophylaxis treatment regimens were analyzed as a single group.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With a Bleeding Episode</title>
            <description>All bleeding episodes treated with BAX 855 in participants on on-demand and prophylaxis treatment regimens.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Success of BAX 855 for Treatment of Bleeding Episodes</title>
          <description>Success in the control of bleeding was defined as a rating of excellent or good using the Efficacy Rating Scale for Treatment of Bleeding Episodes measured 24 hours after initiation of treatment for the bleeding episode. EXCELLENT: Full relief of pain and cessation of objective signs of bleeding (eg, swelling, tenderness, and decreased range of motion in the case of musculoskeletal hemorrhage) after a single infusion. No additional infusion is required for the control of bleeding. Administration of further infusions to maintain hemostasis would not affect this scoring. GOOD: Definite pain relief and/or improvement in signs of bleeding after a single infusion. Possibly requires more than 1 infusion for complete resolution. FAIR: Probable and/or slight relief of pain and slight improvement in signs of bleeding after a single infusion. Required more than 1 infusion for complete resolution. NONE: No improvement or condition worsens.</description>
          <population>Full Analysis Set - All bleeding episodes treated with BAX 855 in participants on on-demand and prophylaxis treatment regimens were analyzed as a single group.</population>
          <units>Bleeding episodes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Bleeding episodes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding episodes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="591"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.91" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Number of BAX 855 Infusions Needed for the Treatment of Bleeding Episodes</title>
        <time_frame>From first exposure to BAX 855 until the end of the study, [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm; and 6 months (± 2 weeks) for the on-demand arm].</time_frame>
        <population>Participants from the Full Analysis Set who experienced at least one bleeding episode.</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
            <description>Break-through bleeds during prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
          </group>
        </group_list>
        <measure>
          <title>Average Number of BAX 855 Infusions Needed for the Treatment of Bleeding Episodes</title>
          <population>Participants from the Full Analysis Set who experienced at least one bleeding episode.</population>
          <units>Infusions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="0.80"/>
                    <measurement group_id="O2" value="1.21" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ≤1, 2, 3, 4, 5, 6, or &gt;6 Month Time Intervals Between Bleeding Episodes or no Bleeding Episodes</title>
        <description>Interval between Bleeds in months was calculated as: Observation period for efficacy (in days)/(number of bleeds)*(12/365.2425)</description>
        <time_frame>From first exposure to BAX 855 until the end of the study, [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm; and 6 months (± 2 weeks) for the on-demand arm].</time_frame>
        <population>Study participants from the Full Analysis Set (FAS) who received BAX855 during the study period. Note: one participant was assigned to the prophylactic arm (thus was included in the FAS) and received only ADVATE during the screening period.</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ≤1, 2, 3, 4, 5, 6, or &gt;6 Month Time Intervals Between Bleeding Episodes or no Bleeding Episodes</title>
          <description>Interval between Bleeds in months was calculated as: Observation period for efficacy (in days)/(number of bleeds)*(12/365.2425)</description>
          <population>Study participants from the Full Analysis Set (FAS) who received BAX855 during the study period. Note: one participant was assigned to the prophylactic arm (thus was included in the FAS) and received only ADVATE during the screening period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No bleed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight-adjusted Consumption of BAX 855 - Per Prophylactic Infusion and Pharmacokinetic (PK) Infusion</title>
        <time_frame>Prophylactic Infusion: ≥50 exposure days or 6 months (±2 weeks), whichever occurs last. PK Infusion: PK #1 Pre-infusion within 30 minutes; Post-infusion 10 min, and 0.5, 1, 3, 6, 24, 32, 48, 56 hours (h). PK #2 also at Post-infusion 96h</time_frame>
        <population>Full Analysis Set (FAS) - Note: data analyzed by subsets of FAS (1) participants who received BAX855 prophylactic infusion or (2) BAX855 pharmacokinetic (PK) participants.
Subset of participants who received BAX855 prophylactic infusion: N= 120
Subset of BAX855 pharmacokinetic (PK) participants: N=26</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Weight-adjusted Consumption of BAX 855 - Per Prophylactic Infusion and Pharmacokinetic (PK) Infusion</title>
          <population>Full Analysis Set (FAS) - Note: data analyzed by subsets of FAS (1) participants who received BAX855 prophylactic infusion or (2) BAX855 pharmacokinetic (PK) participants.
Subset of participants who received BAX855 prophylactic infusion: N= 120
Subset of BAX855 pharmacokinetic (PK) participants: N=26</population>
          <units>IU/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Infusions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5941"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Per Prophylactic Infusion (N= 5941 Infusions)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.51" spread="4.556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per PK Infusion (N= 50 Infusions)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.48" spread="2.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight-adjusted Consumption of BAX 855 - Per Treatment of Bleeding Episode (BE) and Per BE for Maintenance of Hemostasis</title>
        <description>Infusions per bleeding episode for maintenance of hemostasis only includes infusions following the resolution of a bleed to maintain hemostasis.</description>
        <time_frame>Treatment of Bleeding Episode (BE): Minor/Moderate BE every 12 to 24 hours until bleeding is resolved; Major BE every 8 to 12 hours until bleeding is resolved. Per BE for Maintenance of Hemostasis: within 48 hours after bleeding episode resolution.</time_frame>
        <population>Full Analysis Set (FAS) - Note: data analyzed by subsets of FAS (1) participants who received BAX855 for treatment of BEs (2) BAX855 for Maintenance of Hemostasis.
Subset of participants who received BAX855 for treatment of BEs: N= 92
Subset BAX855 for Maintenance of Hemostasis participants: N=16</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>All Study Participants who received at least one infusion of BAX855.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight-adjusted Consumption of BAX 855 - Per Treatment of Bleeding Episode (BE) and Per BE for Maintenance of Hemostasis</title>
          <description>Infusions per bleeding episode for maintenance of hemostasis only includes infusions following the resolution of a bleed to maintain hemostasis.</description>
          <population>Full Analysis Set (FAS) - Note: data analyzed by subsets of FAS (1) participants who received BAX855 for treatment of BEs (2) BAX855 for Maintenance of Hemostasis.
Subset of participants who received BAX855 for treatment of BEs: N= 92
Subset BAX855 for Maintenance of Hemostasis participants: N=16</population>
          <units>IU/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Bleeds</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeds</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="592"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Per Treatment of BE (N= 592 bleeds)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.44" spread="28.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per BE for Maintenance of Hemostasis (N=34 bleeds)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.29" spread="34.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events</title>
        <description>Adverse Events (AEs) and Serious Adverse Events (SAEs)</description>
        <time_frame>From first exposure to BAX 855 until the end of the study, [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm; and 6 months (± 2 weeks) for the on-demand arm].</time_frame>
        <population>Safety Analysis Set (SAS) - All participants treated with BAX 855 were analyzed as a single group (ie on-demand and prophylaxis treatment regimens were analyzed as a single group).</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>All Study Participants who received at least one infusion of BAX855.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events</title>
          <description>Adverse Events (AEs) and Serious Adverse Events (SAEs)</description>
          <population>Safety Analysis Set (SAS) - All participants treated with BAX 855 were analyzed as a single group (ie on-demand and prophylaxis treatment regimens were analyzed as a single group).</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE, Moderate, Unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE, Severe, Unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nSAE, Mild, Unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nSAE, Mild, Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nSAE, Moderate, Unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nSAE, Moderate, Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nSAE, Unknown Severity, Unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nSAE, Severe, Unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity - Number of Participants With Positive Inhibitory Antibodies to FVIII, Binding Antibodies to FVIII, PEG-VIII, PEG and Anti-CHO Antibodies at Study Completion/Termination</title>
        <description>Number of participants who received BAX855, with immunogenicity data from study completion/termination visit.
FVIII = factor VIII; PEG-VIII = polyethylene glycol-factor VIII; Anti-CHO = Anti-Chinese hamster ovary</description>
        <time_frame>From first exposure to BAX 855 until the end of the study, [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm; and 6 months (± 2 weeks) for the on-demand arm].</time_frame>
        <population>Safety Analysis Set (SAS) - who received BAX855 during the study period. Note: one participant was assigned to the prophylactic arm but did not receive BAX855 (only received ADVATE, during the screening period).</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
            <description>Twice weekly at a dose of 45 ± 5 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
            <description>10 to 60 ± 5 IU/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity - Number of Participants With Positive Inhibitory Antibodies to FVIII, Binding Antibodies to FVIII, PEG-VIII, PEG and Anti-CHO Antibodies at Study Completion/Termination</title>
          <description>Number of participants who received BAX855, with immunogenicity data from study completion/termination visit.
FVIII = factor VIII; PEG-VIII = polyethylene glycol-factor VIII; Anti-CHO = Anti-Chinese hamster ovary</description>
          <population>Safety Analysis Set (SAS) - who received BAX855 during the study period. Note: one participant was assigned to the prophylactic arm but did not receive BAX855 (only received ADVATE, during the screening period).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inhibitory Antibodies to FVIII (N= 112, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG: Binding Antibodies FVIII (N= 117, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM: Binding Antibodies FVIII (N= 117, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG: Binding Antibodies PEG (N= 117, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM: Binding Antibodies PEG (N= 117, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG: Binding Antibodies PEG-FVIII (N= 117, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM: Binding Antibodies PEG-FVIII (N= 117, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHO-Protein Antibodies (N= 117, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Outcomes: Haemo-SYM Questionnaire, Change in Score From Baseline to End of Study</title>
        <description>The HAEMO-SYM has two subscales: pain and bleeds. HAEMO-SYM subscale scores are calculated by taking the mean of the items in each subscale and transforming them to a 0 (none or absent) to 100 (very severe) scale.
Given that higher scores indicate more severe symptoms on the Haemo-SYM and that the change scores were calculated as the value at study completion minus the value at baseline, a negative change score indicates an improvement (reduction in symptoms). Conversely, a positive change score indicates worsening symptoms.</description>
        <time_frame>Baseline; and end of study visit [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm and 6 months (± 2 weeks) for the on-demand arm].</time_frame>
        <population>Full Analysis Set - Subset of participants with both baseline and study completion HAEMO-SYM scores</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
            <description>Participants with both baseline and study completion HAEMO-SYM scores</description>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
            <description>Participants with both baseline and study completion HAEMO-SYM scores</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes: Haemo-SYM Questionnaire, Change in Score From Baseline to End of Study</title>
          <description>The HAEMO-SYM has two subscales: pain and bleeds. HAEMO-SYM subscale scores are calculated by taking the mean of the items in each subscale and transforming them to a 0 (none or absent) to 100 (very severe) scale.
Given that higher scores indicate more severe symptoms on the Haemo-SYM and that the change scores were calculated as the value at study completion minus the value at baseline, a negative change score indicates an improvement (reduction in symptoms). Conversely, a positive change score indicates worsening symptoms.</description>
          <population>Full Analysis Set - Subset of participants with both baseline and study completion HAEMO-SYM scores</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bleed Severity Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.17" spread="17.05"/>
                    <measurement group_id="O2" value="-4.24" spread="15.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Severity Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="12.50"/>
                    <measurement group_id="O2" value="-0.17" spread="11.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Outcomes - Short Form (SF)-36, Change From Baseline to End of Study</title>
        <description>Change from Baseline to End of Study for SF-36 Questionnaire is provided. Scores for individual SF-36 categories range from 0 to 100 with higher scores representing better health. Given that higher scores indicate better health-related quality of life (HRQoL) and that the change scores were calculated as the value at study completion minus the value at baseline, a negative change score indicates a worsening of HRQoL.</description>
        <time_frame>Baseline; and end of study visit [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm and 6 months (± 2 weeks) for the on-demand arm]</time_frame>
        <population>Full Analysis Set - Subset of participants with both baseline and study completion SF-36 scores</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
            <description>Participants with both baseline and study completion SF-36 Scores</description>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
            <description>Participants with both baseline and study completion SF-36 Scores</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes - Short Form (SF)-36, Change From Baseline to End of Study</title>
          <description>Change from Baseline to End of Study for SF-36 Questionnaire is provided. Scores for individual SF-36 categories range from 0 to 100 with higher scores representing better health. Given that higher scores indicate better health-related quality of life (HRQoL) and that the change scores were calculated as the value at study completion minus the value at baseline, a negative change score indicates a worsening of HRQoL.</description>
          <population>Full Analysis Set - Subset of participants with both baseline and study completion SF-36 scores</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning (N= 97, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="5.27"/>
                    <measurement group_id="O2" value="-2.46" spread="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-physical (N= 97, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="7.36"/>
                    <measurement group_id="O2" value="-3.67" spread="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain (N= 97, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" spread="8.19"/>
                    <measurement group_id="O2" value="0.60" spread="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health (N= 96, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="6.43"/>
                    <measurement group_id="O2" value="-0.28" spread="9.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality (N= 96, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="7.43"/>
                    <measurement group_id="O2" value="0.26" spread="9.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning (N= 97, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="7.54"/>
                    <measurement group_id="O2" value="-3.18" spread="6.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Emotional (N= 97, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="8.46"/>
                    <measurement group_id="O2" value="0.65" spread="7.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health (N= 96, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="7.26"/>
                    <measurement group_id="O2" value="-3.29" spread="7.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score (N= 96, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="5.76"/>
                    <measurement group_id="O2" value="-1.58" spread="4.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score (N= 96, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="7.38"/>
                    <measurement group_id="O2" value="-1.14" spread="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (Pk) - Plasma Half-life (One-stage Clotting Assay)</title>
        <description>Terminal half-life calculated as log_e2/λz where λz is the terminal elimination rate constant.
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
        <time_frame>Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only).</time_frame>
        <population>Pharmacokinetic full analysis set (PKFAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacokinetic Analysis Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Pk) - Plasma Half-life (One-stage Clotting Assay)</title>
          <description>Terminal half-life calculated as log_e2/λz where λz is the terminal elimination rate constant.
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
          <population>Pharmacokinetic full analysis set (PKFAS)</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PK-1: ADVATE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.40" spread="2.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PK-2: BAX 855</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.30" spread="3.838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PK-3: BAX 855, After ≥50 Exposure Days (N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.02" spread="4.922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (Pk) - Mean Residence Time (One-stage Clotting Assay)</title>
        <description>The mean residence time (MRT) w as calculated as total area under the moment curve divided by the total area under the curve starting from the begin of infusion (or the end of infusion if start time is not available).
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
        <time_frame>Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only).</time_frame>
        <population>Pharmacokinetic full analysis set (PKFAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacokinetic Analysis Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Pk) - Mean Residence Time (One-stage Clotting Assay)</title>
          <description>The mean residence time (MRT) w as calculated as total area under the moment curve divided by the total area under the curve starting from the begin of infusion (or the end of infusion if start time is not available).
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
          <population>Pharmacokinetic full analysis set (PKFAS)</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PK-1: ADVATE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.86" spread="3.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PK-2: BAX 855</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.56" spread="5.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PK-3: BAX 855, After ≥50 Exposure Days (N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.65" spread="4.821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (Pk) - Total Body Clearance (One-stage Clotting Assay)</title>
        <description>Clearance in dL/(kg.h) will be calculated as the dose in IU/kg divided by the total area under the curve starting from the begin of infusion (or the end of infusion if start time is not available).
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
        <time_frame>Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only).</time_frame>
        <population>Pharmacokinetic full analysis set (PKFAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacokinetic Analysis Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Pk) - Total Body Clearance (One-stage Clotting Assay)</title>
          <description>Clearance in dL/(kg.h) will be calculated as the dose in IU/kg divided by the total area under the curve starting from the begin of infusion (or the end of infusion if start time is not available).
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
          <population>Pharmacokinetic full analysis set (PKFAS)</population>
          <units>dL/(kg*hours)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PK-1: ADVATE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04551" spread="0.021725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PK-2: BAX 855</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02760" spread="0.020288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PK-3: BAX 855, After ≥50 Exposure Days (N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02474" spread="0.008225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (Pk) - Incremental Recovery Over Time (One-stage Clotting Assay)</title>
        <description>Incremental recovery (IR) in (IU/dL)/ (IU/kg) calculated as: IR = (Cmax– (C pre-infusion)) / (Dose/kg), where C =concentration.
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
        <time_frame>Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only).</time_frame>
        <population>Pharmacokinetic full analysis set (PKFAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacokinetic Analysis Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Pk) - Incremental Recovery Over Time (One-stage Clotting Assay)</title>
          <description>Incremental recovery (IR) in (IU/dL)/ (IU/kg) calculated as: IR = (Cmax– (C pre-infusion)) / (Dose/kg), where C =concentration.
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
          <population>Pharmacokinetic full analysis set (PKFAS)</population>
          <units>(IU/dL)/(IU/kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PK-1: ADVATE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.372" spread="0.5357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PK-2: BAX 855</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.493" spread="0.6944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PK-3: BAX 855, After ≥50 Exposure Days (N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.297" spread="0.6377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (Pk) - Area Under the Concentration Versus Time Curve From 0 to Infinity (AUC0-∞) (One-stage Clotting Assay)</title>
        <description>Calculated by WinNonlin NCA (Model 201, calculation method: Linear Trapezoidal Linear/Log Interpolation).
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
        <time_frame>Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only).</time_frame>
        <population>Pharmacokinetic full analysis set (PKFAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacokinetic Analysis Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Pk) - Area Under the Concentration Versus Time Curve From 0 to Infinity (AUC0-∞) (One-stage Clotting Assay)</title>
          <description>Calculated by WinNonlin NCA (Model 201, calculation method: Linear Trapezoidal Linear/Log Interpolation).
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
          <population>Pharmacokinetic full analysis set (PKFAS)</population>
          <units>(IU*hours)/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PK-1: ADVATE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1168.0" spread="425.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PK-2: BAX 855</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2073.3" spread="778.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PK-3: BAX 855, After ≥50 Exposure Days (N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2008.7" spread="631.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (Pk) - Apparent Volume of Distribution at Steady State (Vss) (One-stage Clotting Assay)</title>
        <description>The apparent volume of distribution at steady state (Vss) will be calculated as: Vss = Clearance * Mean Residence Time.
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
        <time_frame>Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only).</time_frame>
        <population>Pharmacokinetic full analysis set (PKFAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacokinetic Analysis Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Pk) - Apparent Volume of Distribution at Steady State (Vss) (One-stage Clotting Assay)</title>
          <description>The apparent volume of distribution at steady state (Vss) will be calculated as: Vss = Clearance * Mean Residence Time.
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
          <population>Pharmacokinetic full analysis set (PKFAS)</population>
          <units>dL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PK-1: ADVATE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5487" spread="0.20213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PK-2: BAX 855</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4715" spread="0.14602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PK-3: BAX 855, After ≥50 Exposure Days (N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4970" spread="0.15756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (Pk) - Maximum Plasma Concentration (Cmax) (One-stage Clotting Assay)</title>
        <description>Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
        <time_frame>Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only).</time_frame>
        <population>Pharmacokinetic full analysis set (PKFAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacokinetic Analysis Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Pk) - Maximum Plasma Concentration (Cmax) (One-stage Clotting Assay)</title>
          <description>Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
          <population>Pharmacokinetic full analysis set (PKFAS)</population>
          <units>IU/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PK-1: ADVATE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.45" spread="26.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PK-2: BAX 855</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.68" spread="30.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PK-3: BAX 855, After ≥50 Exposure Days (N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.34" spread="29.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (Pk) -Time to Maximum Concentration in Plasma (Tmax) (One-stage Clotting Assay)</title>
        <description>Tmax in hours will be defined as the time to reach Cmax. Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
        <time_frame>Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only).</time_frame>
        <population>Pharmacokinetic full analysis set (PKFAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacokinetic Analysis Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Pk) -Time to Maximum Concentration in Plasma (Tmax) (One-stage Clotting Assay)</title>
          <description>Tmax in hours will be defined as the time to reach Cmax. Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).</description>
          <population>Pharmacokinetic full analysis set (PKFAS)</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PK-1: ADVATE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.296" spread="0.1662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PK-2: BAX 855</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.397" spread="0.2632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PK-3: BAX 855, After ≥50 Exposure Days (N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.467" spread="0.6044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vital Signs From Screening - Temperature</title>
        <time_frame>Screening, week 2, week 4, exposure day 10-15, month 3, study completion/termination</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Vital Signs From Screening - Temperature</title>
          <population>Safety Analysis Set</population>
          <units>Celsius</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N= 118, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.20" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N= 118, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.30" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.40" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exposure day 10-15 (N= 31, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" lower_limit="-0.30" upper_limit="0.10"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.30" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (N= 112, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.20" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.10" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completion/Termination (N= 116, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.20" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.10" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vital Signs From Screening - Pulse Rate</title>
        <time_frame>Screening, week 2, week 4, exposure day 10-15, month 3, study completion/termination</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Vital Signs From Screening - Pulse Rate</title>
          <population>Safety Analysis Set</population>
          <units>beats per minute</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N= 118, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="-3.0" upper_limit="9.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-3.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N= 117, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-4.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-5.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exposure day 10-15 (N= 31, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="-3.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="0.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (N= 112, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-5.5" upper_limit="6.5"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-6.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completion/Termination (N= 116, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-6.0" upper_limit="8.5"/>
                    <measurement group_id="O2" value="3.0" lower_limit="-5.0" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vital Signs From Screening - Respiratory Rate</title>
        <time_frame>Screening, week 2, week 4, exposure day 10-15, month 3, study completion/termination</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
          </group>
          <group group_id="O2">
            <title>On-deamand</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Vital Signs From Screening - Respiratory Rate</title>
          <population>Safety Analysis Set</population>
          <units>breaths per minute</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N= 117, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N= 118, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exposure day 10-15 (N= 31, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (N= 112, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-2.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-2.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completion/Termination (N= 115, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-2.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-2.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Vital Signs From Screening - Blood Pressure</title>
        <description>Systolic Blood Pressure (SBP) Diastolic Blood Pressure (DBP)</description>
        <time_frame>Screening, week 2, week 4, exposure day 10-15, month 3, study completion/termination</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
          </group>
        </group_list>
        <measure>
          <title>Changes in Vital Signs From Screening - Blood Pressure</title>
          <description>Systolic Blood Pressure (SBP) Diastolic Blood Pressure (DBP)</description>
          <population>Safety Analysis Set</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP-Week 2 (N= 118, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-7.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-9.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP-Week 4 (N= 118, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-9.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-5.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP-Exposure day 10-15 (N= 31, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-5.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.5" lower_limit="0.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP-Month 3 (N= 112, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-7.0" upper_limit="7.5"/>
                    <measurement group_id="O2" value="-5.0" lower_limit="-12.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP-Completion/Termination (N= 116, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-10.0" upper_limit="7.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-8.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP-Week 2 (N= 118, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-8.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-9.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP-Week 4 (N= 118, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-6.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="-6.0" lower_limit="-12.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP-Exposure day 10-15 (N= 31, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-9.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="-2.5" lower_limit="-6.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP-Month 3 (N= 112, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-7.0" upper_limit="7.5"/>
                    <measurement group_id="O2" value="-4.0" lower_limit="-9.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP-Completion/Termination (N= 116, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-10.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Clinical Chemistry Laboratory Assessments From Screening - Albumin and Protein</title>
        <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
        <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
          </group>
        </group_list>
        <measure>
          <title>Changes in Clinical Chemistry Laboratory Assessments From Screening - Albumin and Protein</title>
          <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
          <units>g/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin: Week 2 (N= 112, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-2.5" upper_limit="1.0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-2.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin: Week 4 (N= 112, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-3.0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-2.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin: Month 3 (N= 106, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-3.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-2.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin: Completion/Termination (N= 112, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-2.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-2.0" upper_limit="-1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein: Week 2 (N= 115, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-4.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-4.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein: Week 4 (N= 114, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-4.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-5.0" upper_limit="-1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein: Month 3 (N= 109, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-3.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-3.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein: Completion/Termination (N= 114, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-3.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-4.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Clinical Chemistry Laboratory Assessments From Screening - Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase</title>
        <description>Alkaline Phosphatase (Alk Phos); Alanine Aminotransferase (Ala Amino); Aspartate Aminotransferase (Asp Amino)</description>
        <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
        <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
          </group>
        </group_list>
        <measure>
          <title>Changes in Clinical Chemistry Laboratory Assessments From Screening - Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase</title>
          <description>Alkaline Phosphatase (Alk Phos); Alanine Aminotransferase (Ala Amino); Aspartate Aminotransferase (Asp Amino)</description>
          <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
          <units>Units per Liter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alk Phos: Week 2 (N= 115, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-7.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="-5.0" lower_limit="-7.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alk Phos: Week 4 (N= 114, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" lower_limit="-9.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="-4.5" lower_limit="-10.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alk Phos: Month 3 (N= 109, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-9.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="-5.0" lower_limit="-11.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alk Phos: Completion/Termination (N= 114, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-9.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="-5.0" lower_limit="-9.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ala Amino: Week 2 (N= 112, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-4.0" upper_limit="4.5"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-6.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ala Amino: Week 4 (N= 112, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-5.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="-2.5" lower_limit="-7.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ala Amino: Month 3 (N= 106, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-6.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-4.0" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ala Amino: Completion/Termination (N= 112, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-7.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.5" lower_limit="-3.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asp Amino: Week 2 (N= 110, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-2.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-6.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asp Amino: Week 4 (N= 110, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-4.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="-3.5" lower_limit="-7.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asp Amino: Month 3 (N= 103, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-3.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-3.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asp Amino: Completion/Termination (N= 110, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-5.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="3.5" lower_limit="-3.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Clinical Chemistry Laboratory Assessments From Screening - Bicarbonate, Chloride, Glucose, Potassium, Sodium, Blood Urea Nitrogen (BUN)</title>
        <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
        <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
          </group>
        </group_list>
        <measure>
          <title>Changes in Clinical Chemistry Laboratory Assessments From Screening - Bicarbonate, Chloride, Glucose, Potassium, Sodium, Blood Urea Nitrogen (BUN)</title>
          <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bicarbonate: Week 2 (N= 111, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="-1.60" upper_limit="1.40"/>
                    <measurement group_id="O2" value="1.10" lower_limit="-1.50" upper_limit="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate: Week 4 (N= 110, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" lower_limit="-0.90" upper_limit="2.40"/>
                    <measurement group_id="O2" value="0.10" lower_limit="-1.50" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate: Month 3 (N= 111, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" lower_limit="-1.30" upper_limit="1.90"/>
                    <measurement group_id="O2" value="0.60" lower_limit="-1.30" upper_limit="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate: Completion/Termination (N= 117, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" lower_limit="-0.60" upper_limit="2.60"/>
                    <measurement group_id="O2" value="2.20" lower_limit="1.00" upper_limit="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride: Week 2 (N= 115, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-3.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride: Week 4 (N= 114, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-2.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride: Month 3 (N= 109, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride: Completion/Termination (N= 114, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-2.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: Week 2 (N= 112, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" lower_limit="-0.55" upper_limit="0.55"/>
                    <measurement group_id="O2" value="-0.30" lower_limit="-0.80" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: Week 4 (N= 112, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="-0.40" upper_limit="0.70"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-0.50" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: Month 3 (N= 106, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.50" upper_limit="0.50"/>
                    <measurement group_id="O2" value="0.10" lower_limit="-0.50" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: Completion/Termination (N= 115, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.50" upper_limit="0.60"/>
                    <measurement group_id="O2" value="-0.10" lower_limit="-0.50" upper_limit="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: Week 2 (N= 115, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.20" upper_limit="0.30"/>
                    <measurement group_id="O2" value="0.10" lower_limit="-0.20" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: Week 4 (N= 114, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="-0.20" upper_limit="0.30"/>
                    <measurement group_id="O2" value="0.10" lower_limit="-0.10" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: Month 3 (N= 109, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.30" upper_limit="0.30"/>
                    <measurement group_id="O2" value="0.10" lower_limit="-0.10" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: Completion/Termination (N= 114, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.20" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.10" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: Week 2 (N= 115, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-2.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: Week 4 (N= 114, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-3.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: Month 3 (N= 109, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-2.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-2.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: Completion/Termination (N= 114, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-2.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-3.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN: Week 2 (N= 115, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.60" upper_limit="0.70"/>
                    <measurement group_id="O2" value="-0.20" lower_limit="-0.40" upper_limit="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN: Week 4 (N= 113, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.70" upper_limit="0.70"/>
                    <measurement group_id="O2" value="-0.10" lower_limit="-0.30" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN: Month 3 (N= 109, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" lower_limit="-0.30" upper_limit="0.90"/>
                    <measurement group_id="O2" value="-0.40" lower_limit="-0.70" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN: Completion/Termination (N= 114, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" lower_limit="-0.70" upper_limit="1.10"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-1.30" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Clinical Chemistry Laboratory Assessments From Screening - Creatinine, and Bilirubin</title>
        <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
        <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
          </group>
        </group_list>
        <measure>
          <title>Changes in Clinical Chemistry Laboratory Assessments From Screening - Creatinine, and Bilirubin</title>
          <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
          <units>µmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine: Week 2 (N= 115, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-7.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-3.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine: Week 4 (N= 114, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-5.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-6.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine: Month 3 (N= 109, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="-3.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine: Completion/Termination (N= 114, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-4.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="6.0" lower_limit="-4.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin: Week 2 (N= 109, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-3.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="-2.00" lower_limit="-5.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin: Week 4 (N= 109, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-2.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="-0.50" lower_limit="-5.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin: Month 3 (N= 103, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-3.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="-3.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin: Completion/Termination (N= 109, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-3.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="-0.50" lower_limit="-2.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Hematology Laboratory Assessments From Screening – Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes</title>
        <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
        <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
          </group>
        </group_list>
        <measure>
          <title>Changes in Hematology Laboratory Assessments From Screening – Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes</title>
          <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
          <units>giga (10^9) cells per liter (Gi/L)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils: Week 2 (N= 108, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-0.015" upper_limit="0.010"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-0.010" upper_limit="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils: Week 4 (N= 109, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-0.010" upper_limit="0.010"/>
                    <measurement group_id="O2" value="0.005" lower_limit="-0.020" upper_limit="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils: Month 3 (N= 103, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-0.020" upper_limit="0.020"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-0.010" upper_limit="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils: Completion/Termination (N= 107, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" lower_limit="-0.020" upper_limit="0.010"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-0.020" upper_limit="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils: Week 2 (N= 108, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" lower_limit="-0.020" upper_limit="0.050"/>
                    <measurement group_id="O2" value="0.030" lower_limit="0.000" upper_limit="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils: Week 4 (N= 109, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020" lower_limit="-0.020" upper_limit="0.060"/>
                    <measurement group_id="O2" value="0.035" lower_limit="-0.010" upper_limit="0.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils: Month 3 (N= 103, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" lower_limit="-0.040" upper_limit="0.050"/>
                    <measurement group_id="O2" value="0.010" lower_limit="-0.005" upper_limit="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils: Completion/Termination (N= 107, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" lower_limit="-0.030" upper_limit="0.050"/>
                    <measurement group_id="O2" value="0.045" lower_limit="0.010" upper_limit="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: Week 2 (N= 108, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" lower_limit="-0.215" upper_limit="0.140"/>
                    <measurement group_id="O2" value="0.280" lower_limit="-0.070" upper_limit="0.640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: Week 4 (N= 109, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.060" lower_limit="-0.240" upper_limit="0.210"/>
                    <measurement group_id="O2" value="0.175" lower_limit="0.030" upper_limit="0.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: Month 3 (N= 103, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.030" lower_limit="-0.200" upper_limit="0.260"/>
                    <measurement group_id="O2" value="0.130" lower_limit="-0.120" upper_limit="0.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: Completion/Termination (N= 107, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.040" lower_limit="-0.160" upper_limit="0.260"/>
                    <measurement group_id="O2" value="0.030" lower_limit="-0.070" upper_limit="0.460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes: Week 2 (N= 108, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" lower_limit="-0.050" upper_limit="0.070"/>
                    <measurement group_id="O2" value="0.060" lower_limit="-0.050" upper_limit="0.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes: Week 4 (N= 109, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020" lower_limit="-0.060" upper_limit="0.050"/>
                    <measurement group_id="O2" value="-0.010" lower_limit="-0.070" upper_limit="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes: Month 3 (N= 103, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-0.060" upper_limit="0.050"/>
                    <measurement group_id="O2" value="0.020" lower_limit="-0.015" upper_limit="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes: Completion/Termination (N= 107, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" lower_limit="-0.050" upper_limit="0.080"/>
                    <measurement group_id="O2" value="0.060" lower_limit="-0.040" upper_limit="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils: Week 2 (N= 108, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.165" lower_limit="-0.870" upper_limit="0.540"/>
                    <measurement group_id="O2" value="0.060" lower_limit="-0.490" upper_limit="0.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils: Week 4 (N= 109, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.130" lower_limit="-0.680" upper_limit="0.450"/>
                    <measurement group_id="O2" value="-0.140" lower_limit="-0.300" upper_limit="0.540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils: Month 3 (N= 103, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.070" lower_limit="-0.860" upper_limit="0.490"/>
                    <measurement group_id="O2" value="-0.425" lower_limit="-0.725" upper_limit="0.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils: Completion/Termination (N= 107, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.050" lower_limit="-0.820" upper_limit="0.480"/>
                    <measurement group_id="O2" value="0.055" lower_limit="-0.570" upper_limit="1.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets: Week 2 (N= 107, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-21.0" upper_limit="25.0"/>
                    <measurement group_id="O2" value="13.5" lower_limit="-6.5" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets: Week 4 (N= 108, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-19.5" upper_limit="22.5"/>
                    <measurement group_id="O2" value="-8.0" lower_limit="-18.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets: Month 3 (N= 102, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="-21.0" upper_limit="21.0"/>
                    <measurement group_id="O2" value="-3.0" lower_limit="-24.0" upper_limit="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets: Completion/Termination (N= 105, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-20.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-15.0" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: Week 2 (N= 108, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.185" lower_limit="-0.910" upper_limit="0.560"/>
                    <measurement group_id="O2" value="0.030" lower_limit="-0.550" upper_limit="1.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: Week 4 (N= 109, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.180" lower_limit="-0.930" upper_limit="0.640"/>
                    <measurement group_id="O2" value="-0.005" lower_limit="-0.670" upper_limit="0.750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: Month 3 (N= 103, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.040" lower_limit="-1.070" upper_limit="0.620"/>
                    <measurement group_id="O2" value="0.220" lower_limit="-0.760" upper_limit="1.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: Completion/Termination (N= 107, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" lower_limit="-0.900" upper_limit="0.680"/>
                    <measurement group_id="O2" value="0.250" lower_limit="-0.710" upper_limit="1.800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Hematology Laboratory Assessments From Screening – Hematocrit</title>
        <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
        <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
          </group>
        </group_list>
        <measure>
          <title>Changes in Hematology Laboratory Assessments From Screening – Hematocrit</title>
          <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
          <units>Percentage red blood cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N= 107, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" lower_limit="-0.030" upper_limit="0.010"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-0.020" upper_limit="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N= 108, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" lower_limit="-0.020" upper_limit="0.005"/>
                    <measurement group_id="O2" value="-0.010" lower_limit="-0.020" upper_limit="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (N= 102, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-0.020" upper_limit="0.010"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-0.020" upper_limit="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completion/Termination (N= 106, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-0.010" upper_limit="0.020"/>
                    <measurement group_id="O2" value="-0.005" lower_limit="-0.030" upper_limit="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Hematology Laboratory Assessments From Screening – Hemoglobin</title>
        <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
        <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
          </group>
        </group_list>
        <measure>
          <title>Changes in Hematology Laboratory Assessments From Screening – Hemoglobin</title>
          <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
          <units>g/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N= 108, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-5.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="-1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N= 109, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-2.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (N= 103, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-3.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="3.5" lower_limit="-1.5" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completion/Termination (N= 107, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-4.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="4.5" lower_limit="-6.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Hematology Laboratory Assessments From Screening – Erythrocytes</title>
        <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
        <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
          </group>
        </group_list>
        <measure>
          <title>Changes in Hematology Laboratory Assessments From Screening – Erythrocytes</title>
          <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
          <units>TI/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N= 108, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" lower_limit="-0.20" upper_limit="0.10"/>
                    <measurement group_id="O2" value="0.10" lower_limit="-0.20" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N= 109, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.20" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.20" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (N= 103, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.10" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.10" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completion/Termination (N= 107, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.10" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.20" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Lipid Panel Assessments From Screening – Cholesterol; High Density Lipoprotein (HDL); Low Density Lipoprotein (LDL); Triglycerides; and Very Low Density Lipoprotein (VLDL)</title>
        <time_frame>Screening, week 2, week 4, month 3, study completion/termination</time_frame>
        <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
          </group>
          <group group_id="O2">
            <title>On-demand</title>
          </group>
        </group_list>
        <measure>
          <title>Changes in Lipid Panel Assessments From Screening – Cholesterol; High Density Lipoprotein (HDL); Low Density Lipoprotein (LDL); Triglycerides; and Very Low Density Lipoprotein (VLDL)</title>
          <population>Safety Analysis Set - Subset of participants with both screening visit data and follow on time point data.</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol: Week 2 (N= 115, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.130" lower_limit="-0.390" upper_limit="0.200"/>
                    <measurement group_id="O2" value="-0.100" lower_limit="-0.770" upper_limit="0.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol: Week 4 (N= 114, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.050" lower_limit="-0.470" upper_limit="0.240"/>
                    <measurement group_id="O2" value="-0.190" lower_limit="-0.780" upper_limit="0.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol: Month 3 (N= 109, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.070" lower_limit="-0.330" upper_limit="0.360"/>
                    <measurement group_id="O2" value="0.040" lower_limit="-0.220" upper_limit="0.400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol: Completion/Termination (N= 114, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.015" lower_limit="-0.340" upper_limit="0.320"/>
                    <measurement group_id="O2" value="0.080" lower_limit="-0.400" upper_limit="0.480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL: Week 2 (N= 115, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-0.100" upper_limit="0.080"/>
                    <measurement group_id="O2" value="-0.130" lower_limit="-0.190" upper_limit="-0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL: Week 4 (N= 114, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.015" lower_limit="-0.120" upper_limit="0.100"/>
                    <measurement group_id="O2" value="-0.095" lower_limit="-0.130" upper_limit="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL: Month 3 (N= 109, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" lower_limit="-0.110" upper_limit="0.100"/>
                    <measurement group_id="O2" value="-0.020" lower_limit="-0.130" upper_limit="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL: Completion/Termination (N= 114, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" lower_limit="-0.150" upper_limit="0.070"/>
                    <measurement group_id="O2" value="0.030" lower_limit="-0.120" upper_limit="0.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL: Week 2 (N= 114, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.070" lower_limit="-0.330" upper_limit="0.170"/>
                    <measurement group_id="O2" value="-0.090" lower_limit="-0.650" upper_limit="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL: Week 4 (N= 112, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.080" lower_limit="-0.350" upper_limit="0.245"/>
                    <measurement group_id="O2" value="-0.320" lower_limit="-0.470" upper_limit="-0.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL: Month 3 (N= 108, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.030" lower_limit="-0.255" upper_limit="0.380"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-0.410" upper_limit="0.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL: Completion/Termination (N= 113, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.050" lower_limit="-0.310" upper_limit="0.310"/>
                    <measurement group_id="O2" value="-0.050" lower_limit="-0.450" upper_limit="0.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides: Week 2 (N= 115, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0600" lower_limit="-0.4200" upper_limit="0.2600"/>
                    <measurement group_id="O2" value="0.1700" lower_limit="-0.0100" upper_limit="0.3500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides: Week 4 (N= 114, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0800" lower_limit="-0.4000" upper_limit="0.2300"/>
                    <measurement group_id="O2" value="0.1500" lower_limit="-0.2500" upper_limit="0.6200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides: Month 3 (N= 109, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1600" lower_limit="-0.4700" upper_limit="0.2100"/>
                    <measurement group_id="O2" value="0.3600" lower_limit="0.2000" upper_limit="0.5200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides: Completion/Termination (N= 114, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" lower_limit="-0.3800" upper_limit="0.2300"/>
                    <measurement group_id="O2" value="0.1200" lower_limit="-0.0400" upper_limit="0.2100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL: Week 2 (N= 114, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0150" lower_limit="-0.1900" upper_limit="0.1200"/>
                    <measurement group_id="O2" value="0.0800" lower_limit="0.0000" upper_limit="0.1600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL: Week 4 (N= 112, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0350" lower_limit="-0.1800" upper_limit="0.1050"/>
                    <measurement group_id="O2" value="0.0400" lower_limit="-0.1100" upper_limit="0.2400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL: Month 3 (N= 108, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0700" lower_limit="-0.2250" upper_limit="0.0950"/>
                    <measurement group_id="O2" value="0.1600" lower_limit="0.0900" upper_limit="0.2400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL: Completion/Termination (N= 113, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" lower_limit="-0.1700" upper_limit="0.1000"/>
                    <measurement group_id="O2" value="0.0600" lower_limit="-0.0200" upper_limit="0.1000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first exposure to BAX 855 until the end of the study, [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm; and 6 months (± 2 weeks) for the on-demand arm].</time_frame>
      <desc>All study participants were analyzed in a single arm/group.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Study Participants</title>
          <description>All study participants were analyzed in a single arm/group.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>HERPES ZOSTER INFECTION NEUROLOGICAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCLE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>NEUROENDOCRINE CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Baxalta's agreements with PIs may vary per individual PI, but contain common elements. For this study, PIs may be restricted from independently publishing results without prior approval.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brigitt Abbuehl, MD</name_or_title>
      <organization>Baxalta Innovations GmbH</organization>
      <email>brigitt.abbuehl@baxalta.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

